Did Blood DNA Methylation Identify a Brain Change Caused by Methamphetamine?
A DNA methylation difference measured in blood is not direct evidence of a change in brain tissue. Shirai and colleagues compared blood samples from 24 people with methamphetamine dependence and 24 controls. They identified methylation associations, but the design did not establish that methamphetamine caused those differences or that the findings could diagnose a new patient.
The sample and measurement
All participants were of Japanese descent and were studied in Kobe. The control group was matched for age and sex. The investigators extracted genomic DNA from peripheral blood and used a methylation array to examine CpG sites across the genome.
Methylation is an epigenetic modification. An association at a methylation site should not be described as proof that methamphetamine changed the underlying DNA sequence. Nor does a blood-based measurement establish that the same pattern exists in neurons.
What the statistical findings support
The authors reported four CpG sites meeting their epigenome-wide significance criterion, including sites associated with CNOT1 and PUM1. They also explored networks, biological terms and pathways. These analyses addressed patterns associated with group membership in the sampled participants.
The criteria differed across analyses. The paper used correction for multiple testing for its significant individual-site findings, while some enrichment analyses used less stringent exploratory criteria. An exploratory pathway result therefore should not be given the same evidentiary weight as a site that met the study’s corrected threshold.
Adjustment did not remove every alternative explanation
The principal regression included age, sex and smoking history. Smoking was more frequent in the dependence group, and the authors acknowledged that accounting for smoking history might not capture its close relationship with methamphetamine use.
The researchers also considered a model including estimated blood-cell proportions. They selected the first model for further analyses in light of the small sample. Information on other possible influences, including medication use, diet, physical activity, education and adverse childhood experiences, was unavailable. These limits matter when attributing a difference specifically to the drug.
No brain sample or diagnostic validation
The paper explicitly noted that it did not examine brain tissue, messenger-RNA expression or protein expression. A methylation association cannot fill those measurement gaps. Its possible relationship to gene expression remains a further question rather than a demonstrated downstream effect in this study.
The experiment also did not establish the sensitivity and specificity of an independently validated clinical diagnostic test. Separating two research groups statistically is different from correctly classifying a new person in a population where medical histories, ancestry, smoking and other exposures vary.
The limits of an individual inference
This study can support a discussion of blood methylation associations worthy of replication. It cannot identify when a particular person used methamphetamine, establish current impairment, or prove that a specific brain abnormality resulted from the drug. The small, ancestry-specific sample and absence of before-and-after exposure measurements limit causal and population-wide claims.
Source
Shirai T, Okazaki S, Tanifuji T, and colleagues. Epigenome-wide association study on methamphetamine dependence. Addiction Biology. 2024;29:e13383. DOI: 10.1111/adb.13383. Supplied PDF: PMC11061849.



